Abstract：
UNASSIGNED: This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2 (HER2)-low early breast cancer (BC) and HER2-IHC0 BC.
UNASSIGNED: Patients diagnosed with HER2-negative BC ( N = 999) at our institution between January 2011 and December 2015 formed our study population. Clinicopathological characteristics, association between estrogen receptor (ER) expression and HER2-low, and evolution of HER2 immunohistochemical (IHC) score were assessed. Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes (5-year follow-up) between the HER2-IHC0 and HER2-low groups.
UNASSIGNED: HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor (PgR) positivity than HER2-IHC0 BC group ( P < 0.001). The rate of HER2-low status increased with increasing ER expression levels (Mantel-Haenszel χ 2 test, P < 0.001, Pearson\'s R = 0.159, P < 0.001). Survival analysis revealed a significantly longer overall survival (OS) in HER2-low BC group than in HER2-IHC0 group ( P = 0.007) in the whole cohort and the hormone receptor (HR)-negative group. There were no significant differences between the two groups in terms of disease-free survival (DFS). The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.
UNASSIGNED: HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.
UNASSIGNED: Patients diagnosed with HER2-negative BC ( N = 999) at our institution between January 2011 and December 2015 formed our study population. Clinicopathological characteristics, association between estrogen receptor (ER) expression and HER2-low, and evolution of HER2 immunohistochemical (IHC) score were assessed. Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes (5-year follow-up) between the HER2-IHC0 and HER2-low groups.
UNASSIGNED: HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor (PgR) positivity than HER2-IHC0 BC group ( P < 0.001). The rate of HER2-low status increased with increasing ER expression levels (Mantel-Haenszel χ 2 test, P < 0.001, Pearson\'s R = 0.159, P < 0.001). Survival analysis revealed a significantly longer overall survival (OS) in HER2-low BC group than in HER2-IHC0 group ( P = 0.007) in the whole cohort and the hormone receptor (HR)-negative group. There were no significant differences between the two groups in terms of disease-free survival (DFS). The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.
UNASSIGNED: HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.
摘要：
■本研究旨在综合分析和比较中国人表皮生长因子受体2（HER2）-低早期乳腺癌（BC）和HER2-IHC0BC患者的临床病理特征和预后。
■2011年1月至2015年12月在我们机构诊断为HER2阴性BC（N=999）的患者构成了我们的研究人群。临床病理特征,雌激素受体（ER）表达与低HER2之间的关联，评估HER2免疫组织化学（IHC）评分的演变。使用Kaplan-Meier方法和log-rank检验比较HER2-IHC0组和HER2低组之间的长期生存结果（5年随访）。
■HER2低BC组比HER2-IHC0BC组倾向于显示ER的高表达和更多的孕激素受体（PgR）阳性（P<0.001）。HER2低状态的比率随着ER表达水平的增加而增加(Mantel-Haenszelχ2检验，P<0.001，Pearson的R=0.159，P<0.001）。生存分析显示，在整个队列和激素受体（HR）阴性组中，HER2低BC组的总生存期（OS）明显长于HER2-IHC0组（P=0.007）。两组在无病生存期（DFS）方面没有显着差异。原发灶和转移灶HER2IHC评分不一致率为36.84%。
■在这项基于人群的研究中，由于相似的临床病理特征和预后作用，HER2低BC可能不被视为独特的BC组。
■2011年1月至2015年12月在我们机构诊断为HER2阴性BC（N=999）的患者构成了我们的研究人群。临床病理特征,雌激素受体（ER）表达与低HER2之间的关联，评估HER2免疫组织化学（IHC）评分的演变。使用Kaplan-Meier方法和log-rank检验比较HER2-IHC0组和HER2低组之间的长期生存结果（5年随访）。
■HER2低BC组比HER2-IHC0BC组倾向于显示ER的高表达和更多的孕激素受体（PgR）阳性（P<0.001）。HER2低状态的比率随着ER表达水平的增加而增加(Mantel-Haenszelχ2检验，P<0.001，Pearson的R=0.159，P<0.001）。生存分析显示，在整个队列和激素受体（HR）阴性组中，HER2低BC组的总生存期（OS）明显长于HER2-IHC0组（P=0.007）。两组在无病生存期（DFS）方面没有显着差异。原发灶和转移灶HER2IHC评分不一致率为36.84%。
■在这项基于人群的研究中，由于相似的临床病理特征和预后作用，HER2低BC可能不被视为独特的BC组。
